SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+6.98%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$223M
AUM Growth
+$223M
(+29%)
Cap. Flow
+$49.5M
Cap. Flow
% of AUM
22.17%
Top 10 Holdings %
Top 10 Hldgs %
40.82%
Holding
94
New
12
Increased
43
Reduced
11
Closed
23
Top Buys
| 1 |
Galapagos
GLPG
|
$7.11M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$6.41M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$6.24M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$5.92M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$4.87M |
Top Sells
| 1 |
Fulcrum Therapeutics
FULC
|
$5.24M |
| 2 |
NextCure
NXTC
|
$3.17M |
| 3 |
Arvinas
ARVN
|
$3.06M |
| 4 |
Insmed
INSM
|
$2.01M |
| 5 |
Erasca
ERAS
|
$1.98M |
Sector Composition
| 1 | Healthcare | 94.76% |
| 2 | Financials | 4.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xenon Pharmaceuticals
XENE
$2.98B
| $3.12M | 1.27% |
100,000
+80,568
| +415% | +$2.52M |
|
27
Halozyme
HALO
$8.56B
| $2.86M | 1.16% |
71,009
+10,839
| +18% | +$436K |
|
|
28
Insmed
INSM
$28.8B
| $2.74M | 1.11% |
100,621
-73,967
| -42% | -$2.01M |
|
29
Seres Therapeutics
MCRB
$166M
| $2.67M | 1.08% |
320,602
+45,769
| +17% | +$381K |
|
30
Cytokinetics
CYTK
$4.23B
| $2.65M | 1.07% |
58,190
+8,881
| +18% | +$405K |
|
|
OTIC
31
DELISTED
Otonomy, Inc.
OTIC
| $2.5M | 1.01% |
1,199,814
+182,766
| +18% | +$380K |
|
32
Viridian Therapeutics
VRDN
$1.5B
| $2.45M | 0.99% |
123,806
+17,728
| +17% | +$351K |
|
|
VRAY
33
DELISTED
ViewRay, Inc.
VRAY
| $2.36M | 0.96% |
427,847
+242,812
| +131% | +$1.34M |
|
34
Aurinia Pharmaceuticals
AUPH
$1.58B
| $2.29M | 0.93% |
+100,000
| New | +$2.29M |
|
35
EyePoint Pharmaceuticals
EYPT
$797M
| $2.23M | 0.9% |
181,886
+52,596
| +41% | +$644K |
|
36
Syndax Pharmaceuticals
SNDX
$1.41B
| $2.19M | 0.89% |
+100,000
| New | +$2.19M |
|
37
Stereotaxis
STXS
$261M
| $2.13M | 0.86% |
344,236
+52,540
| +18% | +$326K |
|
|
JNCE
38
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.05M | 0.83% |
245,829
+37,270
| +18% | +$311K |
|
39
Cyclacel Pharmaceuticals
CYCC
$18.4M
| $1.78M | 0.72% |
458,466
+69,834
| +18% | +$272K |
|
40
Celldex Therapeutics
CLDX
$1.47B
| $1.74M | 0.71% |
45,132
+6,889
| +18% | +$266K |
|
|
ASLN
41
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $1.68M | 0.68% |
+1,498,192
| New | +$1.68M |
|
|
SGEN
42
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.68M | 0.68% |
10,848
-901
| -8% | -$139K |
|
43
BridgeBio Pharma
BBIO
$9.89B
| $1.67M | 0.68% |
+100,000
| New | +$1.67M |
|
|
PSTX
44
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $1.6M | 0.65% |
+234,932
| New | +$1.6M |
|
|
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.57M | 0.64% |
160,526
+123,277
| +331% | +$1.2M |
|
46
Benitec Biopharma
BNTC
$348M
| $1.54M | 0.62% |
587,499
+89,490
| +18% | +$234K |
|
47
Biogen
BIIB
$19.4B
| $1.38M | 0.56% |
5,744
+1,355
| +31% | +$325K |
|
|
ELOX
48
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $1.36M | 0.55% |
1,930,092
+670,252
| +53% | +$473K |
|
49
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.3M | 0.53% |
131,823
-92,083
| -41% | -$911K |
|
|
MSAC
50
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $1.25M | 0.51% |
128,582
+18,542
| +17% | +$180K |
|